We will have produced new drugs focusing on the three research areas as shown below.
[Infectious disease] [Pain/CNS] [Frontier areas]

Shionogi focuses on infectious diseases and psychiatric and neurological disorders as our core therapeutic areas. In addition, we are pursuing new growth areas such as cancer and sarcopenia. In order to meet medical and social needs, we aim to provide total care for the respective disease, including our core breakthrough drugs as well as prevention and other measures. To this end, while focusing on its strengths in small-molecule drugs, Shionogi is researching to acquire new therapies such as digital medicine, and technologies to help with diagnosis and prevention.

Infectious disease

Total Care for Infectious Diseases

[Tackle the world's three major infectious diseases] HIV, Tuberculosis, Malaria
The three major infectious diseases (HIV, tuberculosis and malaria) have been major threats and challenges in terms of global health, and from the perspective of the SDGs it is hoped that the disease will be overcome as soon as possible. Moreover, respiratory infections such as influenza and COVID-19 are life-threatening in severe cases, and their rapid spread among people will have an enormous impact on society and economic activity, so immediate solutions are therefore desired. In addition, there is a major social and medical need around infectious diseases that are difficult to cure by existing drugs, as well as emerging infectious diseases that are difficult to predict when they will occur.
In order to free ourselves from such threats of infectious diseases, Shionogi will continue to promote the discovery of innovative new drugs, as well as take the challenge of providing total care of infectious diseases through diverse approaches. We are actively engaged in research and development to ensure that appropriate measures can be taken at every point, by reducing the risk of onset and severity of disease through vaccines, rapid identification of disease through simple diagnostic methods, elimination or reduction of pathogens through highly effective therapeutic agents, and prevention of severe disease through control of the host response.

Psychiatric disorders and neurological diseases

Our hope is to create a society where patients suffering from psychiatric and neurological disorders and their families as well as the people around them are relieved of their worries, so that they can play active roles in their lives. With this in mind, we are working hard to research and develop better treatments for psychiatric and neurological disorders.

  • Dementia: Alzheimer's disease is the most prevalent form of dementia. Patients with Alzheimer’s disease suffer from more problems than memory and learning disabilities. We are promoting research to solve these problems by providing innovative solutions for the diagnosis, treatment and prevention of Alzheimer's disease.
  • Attention-deficit hyperactivity disorder (ADHD): ADHD is one of neurodevelopmental disorder (developmental disabilities) that is primarily characterized by inattention (inability to concentrate and easily distracted), hyperactivity and impulsivity (inability to sit still and wait for a turn), and is treated with psychosocial treatment, support and medical intervention. In order to relieve the problems associated with developmental disabilities including ADHD, we are promoting research for not only pharmacological therapies, but also non-pharmacological therapies such as digital therapy.
  • Psychiatric disorders (depression): Depression is a psychiatric disorder with depressive symptoms including a depressed mood or loss of interest and pleasure as primary symptoms. While it has a significant impact on patients' quality of life, there are many cases of inadequate response to treatment, high recurrence rates, and long treatment duration. We are conducting research of new treatments for depression, which would help to improve patients' quality of life and to address unmet needs.
  • Pain: Pain is an important factor that not only significantly reduces a patient's quality of life, but also influences the treatment and prognosis of the underlying disease. We are continuing research to develop pain medications with strong analgesic effect without showing adverse effects. In addition, we are also promoting research for diagnostic methods and providing information that lead to the appropriate use of analgesics, by which we desire to contribute to help patients and healthcare professionals.

New growth areas

  • Cancer: Cancer is the leading cause of death in many countries and is a serious life and health issue. It often causes anxiety not only for the patient, but also for their family members and acquaintances. In addition, its long-term treatment sometimes leads to employment problems. In recent years, immune checkpoint inhibitors have significantly changed the treatment of cancer, and the potential of the immune response to tumors has been gaining attention. We are committed to providing a variety of treatment options by developing diverse and unique immuno-oncology assets with different mechanisms of action.
  • Sarcopenia/frailty: Life expectancy has increased in recent years and most developed countries are reaching 100 years of life. With such a long lifetime, it would become important to increase the length of time we can stay healthy as long as possible, i.e., to extend our healthy life expectancy. On the other hand, as we age, our physical functioning declines and there can be a gap between healthy life expectancy and individual life expectancy. We are committed to the discovery of drugs and development of therapeutic methods for the treatment of locomotor dysfunctions that can lead to the need for care and support.